Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical Therapeutics

• Publication date

  2008-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clinthera.2008.05.004PMID 18555933
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

  2007cited by this paper
• Comment on: Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50:259–267

  2007cited by this paper
• Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans

  2006cited by this paper
• Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

  2005cited by this paper
• Pharmacokinetics of an Oral Drug (Acetaminophen) Administered at Various Times in Relation to Subcutaneous Injection of Exenatide (Exendin‐4) in Healthy Subjects

  2005cited by this paper
• Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes

  2005cited by this paper
• Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.

  2004cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.

  2004cited by this paper
• Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.

  2003cited by this paper
• Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

  2003cited by this paper
• Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.

  2003cited by this paper
• Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease

  2002cited by this paper
• Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers.

  2001cited by this paper
• Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.

  2001cited by this paper
• World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

  2000cited by this paper
• Comparison of Fasting and 2-Hour Glucose and HbA1c Levels for Diagnosing Diabetes: Diagnostic criteria and performance revisited

  1997cited by this paper
• Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance.

  1996cited by this paper
• Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes

  1994cited by this paper
• Textbook of Diabetes

  1991cited by this paper
• The Application of the Principle of Intention–to–Treat to the Analysis of Clinical Trials

  1991cited by this paper
• Postchallenge Glucose Concentration and Coronary Heart Disease in Men of Japanese Ancestry: Honolulu Heart Program

  1987cited by this paper
• The Analysis of Variance

  1960cited by this paper

• Exploring the rates of Gastrointestinal adverse effects among five GLP-1 receptor agonists: A systematic review and Meta-Analysis of randomized controlled trials

  2026cites this paper
• The Molecular Actions of Myricetin and Targeting Cell Signalling Pathways in Cancer Treatment

  2025cites this paper
• The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes

  2022influential citation
• The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia

  2022cites this paper
• Distinct Identity of GLP-1R, GLP-2R, and GIPR Expressing Cells and Signaling Circuits Within the Gastrointestinal Tract

  2021cites this paper
• Potential of Glucagon-Like Peptide 1 as a Regulator of Impaired Cholesterol Metabolism in the Brain.

  2020cites this paper
• Cholesterol Absorption

  2020cites this paper
• Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan‐L trial

  2019cites this paper
• An experimental study of exenatide effects on renal injury in diabetic rats

  2019cites this paper
• Effect of liraglutide on dietary lipid‐induced insulin resistance in humans

  2018cites this paper
• Racial and Ethnic Disparities in Prevalence and Care of Patients With Type 2 Diabetes

  2017influential citation
• Investigation of phytonutrients in the treatment of cardio-metabolic disease

  2016cites this paper
• Postprandial plasma glucose effects of once-weekly albiglutide for the treatment of type 2 diabetes

  2016cites this paper
• The effect of exercise in NAFLD and a GLP-1 receptor agonist in type 2 diabetes on lipid metabolism.

  2016cites this paper
• Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans

  2015cites this paper
• Gut Peptides Are Novel Regulators of Intestinal Lipoprotein Secretion: Experimental and Pharmacological Manipulation of Lipoprotein Metabolism

  2015cites this paper
• A porcine type 1 Diabetes Mellitus model, for non-invasive in vivo imaging of the glucagon-like peptide-1 receptor in the pancreas, using [68Ga]Ga-DO3A-VS-Cys40-conjugated synthetic exendin-4 in PET-CT

  2015cites this paper
• Central Nervous System Regulation of Intestinal Lipoprotein Metabolism by Glucagon-Like Peptide-1 via a Brain–Gut Axis

  2015cites this paper
• Brief review A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes

  2015cites this paper
• A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes

  2015cites this paper
• Racial/ethnic disparities in prevalence and care of patients with type 2 diabetes mellitus

  2015cites this paper
• Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients

  2014cites this paper
• Recent advances in pharmacotherapy for hypertriglyceridemia.

  2014cites this paper
• Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide

  2014cites this paper
• Obesity Diabetes mellitus Oral estrogens ; selective estrogen receptor modulators Physical inactivity Polycystic ovary syndrome Beta-blockers Diet high in fat and simple sugars Hypothyroidism Thiazides Excessive alcohol consumption Nephrotic syndrome , chronic renal disease Atypical antipsychotics C

  2014influential citation
• Exenatide Twice Daily: A Review of Its Use in the Management of Patients with Type 2 Diabetes Mellitus

  2014cites this paper
• New and emerging regulators of intestinal lipoprotein secretion.

  2014cites this paper
• Obesity and Metabolic Syndrome

  2014cites this paper
• What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus?

  2013cites this paper
• Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies

  2013cites this paper
• Traitement du diabète de type 2 : l’exénatide, en alternative ou en association à l’insuline ?

  2013cites this paper
• Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states

  2012cites this paper
• Regulation of chylomicron production in humans.

  2012cites this paper
• Postprandial dyslipidaemia and diabetes: mechanistic and therapeutic aspects

  2012cites this paper
• Physiological, Morphological and molecular biological studies of the effect of Glucagon-like peptide-1 and exenatide in the diabetic rat pancreas

  2012cites this paper
• Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans

  2012cites this paper
• Chapter 4 One-year exenatide and insulin glargine treatment improves prandial beta-cell response in metformin treated patients with type 2 diabetes

  2011cites this paper
• Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes

  2011cites this paper
• Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study

  2011cites this paper
• [Incretin-based therapy for treating patients with type 2 diabetes].

  2011cites this paper
• Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins

  2011influential citation
• Gut-liver interaction in triglyceride-rich lipoprotein metabolism.

  2011cites this paper
• Newly appreciated therapeutic effect of GLP-1 receptor agonists: reduction in postprandial lipemia.

  2010cites this paper
• Non‐Insulin Parenteral Therapies

  2010cites this paper
• Improvement of Postprandial Endothelial Function After a Single Dose of Exenatide in Individuals With Impaired Glucose Tolerance and Recent-Onset Type 2 Diabetes

  2010cites this paper
• Managing diabetic peripheral neuropathic pain in primary care.

  2010influential citation
• Insulin Glargine : Effects on postprandial lycemia , lipid profiles , and oxidative stress

  2010cites this paper
• The importance and treatment of postprandial hyperglycemia.

  2010cites this paper
• Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.

  2010cites this paper
• One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress.

  2010cites this paper
• The effect of antidiabetic drugs on genes regulating lipid metabolism

  2009cites this paper
• Oralni hipoglikemizantni lijekovi u liječenju šećerne bolesti

  2009cites this paper
• Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes

  2009cites this paper
• Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results.

  2009cites this paper
• Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

  2009cites this paper
• Send Orders of Reprints at Reprints@benthamscience.net Evolution of Exenatide as a Diabetes Therapeutic

  year unknowncites this paper